A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma
Running, not enrolling · Phase 1
Conditions studied: Pancreatic Ductal Adenocarcinoma
In brief
This study has stopped recruitment. Adults with advanced pancreatic cancer participate in this study. The study tests a type of immunotherapy. It is a protein treatment (ATP150/ATP152/ATP162) combined with a virus (VSV-GP154) that may kill cancer cells and help the immune system fight cancer. The immunotherapy is combined with a study medicine called ezabenlimab. Ezabenlimab is an antibody that may also help the immune system fight cancer. The purpose is to find the highest dose of the immunotherapy that people with pancreatic cancer can tolerate when taken alone or together with ezabenlimab (Part A and B). To find out, researchers look at the number of participants with certain severe health problems. The original purpose of the subsequent Part C was to check whether the immunotherapy combined with ezabenlimab may increase survival and prevent the cancer getting worse over time. The recruitment into Part C was not continued and stopped. Participants can stay in the study as long as they tolerate the treatment or up to 1 year. During that time, they regularly visit the site. At all visits, the doctors closely check the health of the participants and note any severe health problems.
Key facts
- Study ID
- NCT05846516
- Run by
- Boehringer Ingelheim
- People needed
- 59
- Starts
- 2023-05-11
- Expected to finish
- 2027-03-08
- Last updated by the study team
- 2026-07-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Southern California — Los Angeles, California, United States
- University of California Los Angeles — Santa Monica, California, United States
- University of Colorado Cancer Center — Aurora, Colorado, United States
- University of Florida — Gainesville, Florida, United States
- Orlando Health Cancer Institute — Orlando, Florida, United States
- Karmanos Cancer Institute — Detroit, Michigan, United States
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island — New York, New York, United States
- University Hospitals Cleveland Medical Center — Cleveland, Ohio, United States
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
- START South Texas Accelerated Research Therapeutics, LLC — San Antonio, Texas, United States
- Virginia Cancer Specialists, PC — Fairfax, Virginia, United States
- Virginia Mason Medical Center — Seattle, Washington, United States
- Asklepios Kliniken Hamburg GmbH — Hamburg, Germany
- Hospital Universitario Reina Sofía — Córdoba, Spain
- Hospital General Universitario Gregorio Marañón — Madrid, Spain
- Hospital Universitario Fundacion Jimenez Diaz — Madrid, Spain
- Clara Campal Comprehesive Cancer Center — Madrid, Spain
- University Hospital Bern — Bern, Switzerland
- Hopitaux Universitaires de Geneve (HUG) — Geneva, Switzerland
- Centre Hospitalier Universitaire Vaudois (CHUV) — Lausanne, Switzerland
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.